Plasticell, a developer of stem cell technologies and regenerative medicines, has announced that it has been contracted by the Ministry of Defence (MoD) in a pilot programme to develop regenerative medicines for the treatment of injuries resulting from combat or terrorism. Plasticell will deploy its combinatorial stem cell screening platform, CombiCult®, to develop technologies for the conversion of pluripotent stem [...]

UK’s innovation agency provides funding to develop advanced technologies for the manufacturing of autologous ex vivo gene therapies. Plasticell, a developer of stem cell technologies and therapies, has announced it is leading a consortium of pioneering gene therapy groups at UCL Great Ormond Street Institute of Child Health (ICH) to develop advanced technologies for the manufacturing of ex vivo gene [...]

Plasticell, a developer of innovative stem cell technologies and cell therapies, today announced it will collaborate with Anthony Nolan, a leading research organisation dedicated to saving the lives of people with blood cancers, to progress clinical development of Plasticell’s ex vivo expanded cord blood-derived hematopoietic stem cell product. Allogeneic haematopoietic stem cell transplantation (HSCT) is a curative therapy for patients [...]

Plasticell, the biotechnology company specialising in stem cell screening and cell therapy development, has entered into a collaboration with GSK to use its combinatorial stem cell screening technology, CombiCult®, to optimise the directed differentiation of induced pluripotent stem cells (iPSCs) to specific blood cell lineages for use by GSK in its therapeutic research. In the collaboration, Plasticell will use its [...]

Plasticell, a developer of cell therapies including hematopoietic cell replacement therapies, today announced it has partnered with Kings College London to progress preclinical trials of its artificial blood platelet product, manufactured from pluripotent stem cells. The work is supported by a MedCity research grant which funds collaboration between leading SMEs and academics from London universities. Over 10 million units of [...]

Plasticell, a developer of cell therapies including hematopoietic cell replacement therapies, today announced it has secured Biomedical Catalyst funding of over £920,000 from Innovate UK to create a safe, effective red blood cell substitute for human clinical transfusion, in collaboration with stem cell scientists at the University of Edinburgh. Over 90 million blood transfusions are carried out worldwide each year [...]

Plasticell, a developer of stem cell technologies and cell-based therapies, has announced that it has signed agreements with the Agency for Science, Technology and Research (A*STAR) and the Nanyang Technological University (NTU) to progress its therapeutic stem cell pipeline. “We are delighted to have put together this collaboration with has such enormous potential for the creation of next-generation stem cell [...]